about
Discovery of biphenylacetamide-derived inhibitors of BACE1 using de novo structure-based molecular design.Prion protein is decreased in Alzheimer's brain and inversely correlates with BACE1 activity, amyloid-β levels and Braak stageBIN1 is decreased in sporadic but not familial Alzheimer's disease or in aging.Prion protein interacts with BACE1 protein and differentially regulates its activity toward wild type and Swedish mutant amyloid precursor protein.Elevation of brain glucose and polyol-pathway intermediates with accompanying brain-copper deficiency in patients with Alzheimer's disease: metabolic basis for dementia.Ablation of Prion Protein in Wild Type Human Amyloid Precursor Protein (APP) Transgenic Mice Does Not Alter The Proteolysis of APP, Levels of Amyloid-β or Pathologic PhenotypeThe Role of Tissue Non-specific Alkaline Phosphatase (TNAP) in Neurodegenerative Diseases: Alzheimer's Disease in the Focus.Alkaline phosphatase is increased in both brain and plasma in Alzheimer's disease.Tau pathology and neurochemical changes associated with memory dysfunction in an optimised murine model of global cerebral ischaemia - A potential model for vascular dementia?Tau Proteolysis in the Pathogenesis of Tauopathies: Neurotoxic Fragments and Novel Biomarkers.Plasma metals as potential biomarkers in dementia: a case-control study in patients with sporadic Alzheimer's disease.Modelling Sporadic Alzheimer's Disease Using Induced Pluripotent Stem CellsQuantitative interaction proteomics reveals differences in the interactomes of amyloid precursor protein isoformsProteolytic shedding of the prion protein via activation of metallopeptidase ADAM10 reduces cellular binding and toxicity of amyloid-β oligomersProteolysis of the low density lipoprotein receptor by bone morphogenetic protein-1 regulates cellular cholesterol uptake
P50
Q34571962-E9269822-62B8-476F-860A-DE9F3EE4E896Q34663576-1937CF06-3418-498B-8D5A-D71AF18ADA39Q35036731-338C36D5-E418-44F1-BC1A-B0291B392702Q35313016-C7A9B77C-9778-4305-89D5-075E3F8B90E0Q36985886-E03E6EF2-0573-404A-B7F0-F3ACE9C7FD67Q37119331-39FB6811-31EF-4352-BA2E-6C5BF4A493F3Q40685300-507D94B9-0B5E-4C8B-AD86-4970B6EC813BQ48822486-3BCE2FB6-4B66-414C-B783-28CE080C4677Q52591685-47064177-86E1-4D54-93B2-32EDED20C57DQ52598834-FD5B2F3B-9A47-4271-A58D-097A40E292AEQ52667726-FF10804B-AEE5-45D1-95E3-2BA5DB551D6BQ58570905-3538C19E-901F-4DAD-9720-16AEC44602FCQ61833055-346798B3-D0A4-4639-87E2-21F575B0B293Q64093749-C3A21D39-AE49-4AD2-8905-9A075B546F8EQ92460674-6AF18669-3E3C-4686-BA65-ADE7664B4032
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Katherine A B Kellett
@en
Katherine A B Kellett
@nl
type
label
Katherine A B Kellett
@en
Katherine A B Kellett
@nl
prefLabel
Katherine A B Kellett
@en
Katherine A B Kellett
@nl
P31
P496
0000-0002-2802-0615